(NASDAQ: SRPT) Sarepta Therapeutics's forecast annual revenue growth rate of -15.82% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 105.75%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.68%.
Sarepta Therapeutics's revenue in 2025 is $2,413,715,000.On average, 29 Wall Street analysts forecast SRPT's revenue for 2025 to be $219,633,943,952, with the lowest SRPT revenue forecast at $172,794,071,363, and the highest SRPT revenue forecast at $240,800,955,726. On average, 29 Wall Street analysts forecast SRPT's revenue for 2026 to be $171,117,476,371, with the lowest SRPT revenue forecast at $125,954,198,774, and the highest SRPT revenue forecast at $247,716,910,068.
In 2027, SRPT is forecast to generate $158,019,077,996 in revenue, with the lowest revenue forecast at $108,664,312,919 and the highest revenue forecast at $228,436,067,660.